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Induction of tolerance for skin allotransplantation requires selective suppression of the host
response to foreign histocompatibility antigens. This report describes a new approach which
employs pre-treatment with 8-methoxypsoralen (8-MOP) and ultraviolet A light (UVA) to
render the effector cells of graft rejection immunogenic for the syngeneic recipient. Eight days
after BALB/c mice received CBA/j skin grafts, their splenocytes were treated with 100 ng/ml
8-MOP and 1 J/cm2 UVA prior to reinfusion into naive BALB/c recipients. Recipient mice were
tested for tolerance to alloantigens in mixed leukocyte culture (MLC), cytotoxicity (CTL),
delayed-type hypersensitivity assays (DTH), and challenge with a fresh CBA/j graft.
Splenocytes from BALB/c recipients of photoinactivated splenocytes containing the effector
cells of CBA/j alloantigen rejection proliferated poorly in MLC and generated lower cytotoxic
T-cell responses to CBA/j alloantigens in comparison with sensitized and naive controls and
suppressed the MLC and CTL response to alloantigen from sensitized and naive BALB/c mice.
In vivo, the DTH response was specifically suppressed to the relevant alloantigen in comparison
with controls. BALB/c mice treated in this fashion retained a CBA/j skin graft for up to 42 days
post-transplantation without visual evidence of rejection. These results showed that reinfusion of
photoinactivated effector cells resulted in an immunosuppressive host response which specifically
inhibited in vitro and in vivo responses that correlate with allograft rejection and permitted
prolonged retention of histoincompatible skin grafts.
The capacity selectively to down-regulate aberrant T-cell populations is an impor-
tant goal of immunotherapy. Efforts in that direction have been made in a laboratory
model of autoreactive disease in which cloned anti-myelin basic protein T cells induce
experimental autoimmune encephalomyelitis (EAE) in susceptible strains of rodents
[I]. Cohen et al. [2,3] have shown that, if these pathogenic cloned T cells are
extracorporeally inactivated with methods that alter membrane fluidity (such as
hydrostatic pressure) and then intravenously reinfused, they can immunoprotect
syngeneic animals in a clonotypic manner against the same autoreactive disease.
Among the obstacles that currently preclude application of that approach to
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treatment of human diseases reflecting increased numbers or activity of pathogenic T
cells are the difficulty in isolation, in vitro expansion, and in identifying such aberrant
clones. Finally, it would be necessary that the mode of cell treatment be less
systemically toxic than standard therapies currently available.
Recently, we have reported that cutaneous T-cell lymphoma (CTCL) patients who
received intravenous reinfusion of mononuclear cells which have been extracorporeally
exposed to 8-methoxypsoralen in the presence of ultraviolet A light (UVA), demon-
strated a profound and prolonged clinical response which appears to be immunologi-
cally mediated [4]. It is noteworthy that systemic toxicity wasquite limited. Ifit can be
demonstrated that this clinically practical therapy leads to a specific regulatory T-cell
response, a potentially significant therapeutic principle may have been recognized:
unfractionated populations of autologous mononuclear cells containing an expanded
clone(s) ofpathogenic T cells can immunize against the activity ofthe same clone(s) if
extracorporeally altered in an appropriate fashion.
After the introduction of a histoincompatible tissue transplant, populations of
delayed-type hypersensitivity (Tdth) and cytotoxic effector T cells (Tc) are expanded,
antibody directed against the graft antigens is produced. This immune response leads
to the destruction and rejection of the transplanted tissue [5]. Class I and Class II
cell-surface molecules encoded by genes within the major histocompatibility complex
serve as the main targets of allogeneic responses between genetically unrelated
individuals [6]. Tdth responses are largely directed at Class II antigens [7], and Tc are
mainly directed at Class I molecules [8]. The antigen-binding receptor for target Class
I and 11 molecules is the relevant T-cell receptor (TCR) [9].
Prolonged survival of skin allografts is difficult to achieve due to the particularly
vigorous host immune response to histoincompatible antigens associated with this
organ. Therefore, the efficacy of protocols intended to inhibit the effector T cells
mediating rejection of skin allografts can be demonstrated in this sensitive system.
Andersson, Binz, and Wigzell [10] have reported that specific immune unresponsive-
ness can be induced in vivo in rodents, by immunizing the animal with autologous
antigen-specific lymphoblasts obtained after in vitro sensitization, fractionation, and
emulsification in Freund's complete adjuvant. Thus, autoimmunization against clono-
typic determinants, presumably of the TCR for a given potent antigen, may constitute
an efficient way of producing specific immune tolerance in immunocompetent adult
animals.
To inhibit selectively the response to alloantigen, we exploited the observation that
the antigen receptor ofeffector T cells can be immunogenic and that specific reactions
against TCR can suppress its function [ I1]. In order to inhibit the proliferation of the
effector cells of allogeneic responses, we selected a pharmacologic method of photo-
inactivation by treating the cells with 8-methoxypsoralen (8-MOP) and ultraviolet A
light (UVA), which would permit retention of an intact cell membrane. 8-MOP, a
naturally occurring furocoumarin, has the remarkable capacity of being activated by
UVA from a biologically inert form to one capable of forming covalent bonds with
pyrimidine bases of DNA [12]. The DNA effect induced by 8-MOP is analogous to the
chemical impact of a bifunctional alkylating agent like mitomycin C. Psoralen
photoaddition can be more exquisitely titrated, however, by altering both drug level
and UVA intensity. We have previously established conditions for UVA-/8-MOP-
induced DNA cross-links to inhibit mitosis by murine mononuclear cells maximally
while simultaneously sparing the lymphocytes' capacity to serve as stimulators [13], in
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MLC. This procedure requires an irradiance of 1 joule/cm2 UVA in the presence of
100 ng/ml of 8-MOP.
The following experiments were conducted to determine whether pre-exposure of
BALB/c mice immune system to splenocytes obtained from other BALB/c mice,
undergoing rejection ofCBA/j skin grafts and inactivated with 8-MOP photoactivated
by UVA light, would render the syngeneic recipients unresponsive to the CBA/j
alloantigens as tested by in vitro and in vivo assays, which correlate with allograft
rejection. In this report, we show that pre-exposure of the mouse immune system to
cells generated during skin transplant rejection and photoinactivated with 8-MOP and
UVA can be one way to render the secondary syngeneic recipients relatively tolerant to
the alloantigen carried by the original skin transplant.
MATERIALS AND METHODS
Mice
BALB/cBYJ (H-2d, Mlsb), CBA/j (H-2k, Mlsd), and C57BL/10 (H-2b, Mlsb) mice
were purchased from The Jackson Laboratory, Bar Harbor, ME. All mice were
maintained in a specific pathogen-free facility. Female CBA/j mice four to six weeks
of age were used as skin transplant donors. Female BALB/c mice four to six weeks of
age were the skin transplant recipients. C57BL/10 (H-2b, Mlsb) female mice were the
donors of splenocytes used as the irrelevant alloantigen control in in vitro and in vivo
experiments.
Skin Transplantation and Preparation ofCellSuspension
The skin grafting was performed following the procedure of Billigham and Meda-
war [14]. The truncal skin of donor mice (CBA/j) was shaved and the animals were
sacrificed. Full-thickness skin was obtained by sharp dissection of truncal skin,
followed by removal of fat and panniculus carnosus by blunt dissection. Skin graft
recipient mice (BALB/c) were shaved and anesthetized intramuscularly with .01 ml of
Ketamine hydrochloride (100 mg/ml), diluted 10:1 with Xylasine (20 mg/ml). A
circular piece of skin measuring approximately 1 x 1 cm was removed from each
recipient mouse down to fascia from the grafting site. The grafts were applied to the
fascia and sutured with Vycril 3-0 suture (Ethicon, Johnson & Johnson Co.,
Somerville, NJ). Rejection was allowed to take place. Eight, 12, and 15 days after
transplant, spleens were removed from the mice undergoing allograft rejection.
Single-cell suspensions were prepared, and red cells were lysed with 0.83 percent
NH4Cl. After two washings, cells were adjusted to the appropriate concentration in
phosphate saline buffer (PBS) for injections (see immunization protocol) or media
(culture media consisting of RPMI 1640 supplemented with 20 mM Hepes buffer, 2
mM glutamine, 5 percent heat-inactivated fetal calf serum (FCS) (all from Gibco,
Grand Island, NY), 5 x 10-5 M 2-mercaptoethanol, 100,ug/ml streptomycin, and 100
U/ml penicillin for assays (see MLC, Cytotoxicity Assay, and so on). The cell
suspension was 89 percent viable as determined by trypan blue exclusion. Mean spleen
cell yield was calculated for all splenocytes obtained from BALB/c mice undergoing
CBA/j skin allograft rejection, and cytotoxicity assays were performed at the different
time intervals mentioned (see cytotoxicity assay). Degree of rejection was defined as
the product of mean cell yield and the highest cytotoxic response obtained. By this
definition, the peak of rejection was considered to be eight days post-transplant.
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Splenocytes obtained from these transplanted (sensitized) mice served as a source of
the immunizing population ofcells.
Photoinactivation
Optimal conditions for murine splenocyte photoinactivation, as determined by their
proliferative response to nonspecific mitogens, has been reported elsewhere [13].
8-MOP (Elder Pharmaceutical, Costa Mesa, CA) wasdissolved in 100 percent ethanol
and subsequently in PBS. Splenocytes from BALB/c mice rejecting CBA/j skin graft
were incubated in 100 ng/ml of 8-MOP in shielded tubes for 20 minutes. The cell
suspension was dispensed into Petri dishes (Falcon, Becton Dickinson & Co., Oxnard,
CA) and exposed to 1 j/cm2 of UVA. The irradiation unit consisted of six black light
bulb fluorescent tubes (40 Sylvania), emitting broad-band UVA energy (320-400
nm). Emission in the UVB range was filtered out by a sheet ofwindow glass. Light dose
was monitored by a photometer (International Light, IL 700A), equipped with a UVA
probe. The cell suspension was aseptically collected and washed twice with PBS to
remove the excess 8-MOP.
Immunization Protocol
Recipient mice were injected intravenously in the tail vein with 200 ,ul of PBS
containing 30-50 x 1o6cells. Among these cells was the in vivoexpanded population of
photoinactivated effector T (PET) cells mediating CBA/j skin allograft rejection.
BALB/c recipients were injected once every week for three months. Recipient mice
were then tested for T-cell unresponsiveness to CBA/j alloantigens in mixed leukocyte
culture (MLC), cytotoxicity (CTL), and delayed-type hypersensitivity (DTH) assays
and challenged with fresh CBA/j skin transplants.
MLC
MLC responses were performed following modifications of the methods of Rock et
al. [1 5] and Kruisbeek et al. [16] and represent the in vitro proliferative response to
histoincompatible Class 11 alloantigens [17]. Erythrocyte-free X-irradiated (1,800
rads) skin donor stimulator splenocytes (CBA/j) were suspended in media and
aliquoted at a concentration of 2 x 105 cells/well in a volume of 50 ,l. Increasing
numbers of responder cells (1, 2, 4, and 8 x 105) from either naive, sensitized, or
PET-treated BALB/c mice were cultured in triplicate with 2 x 105 irradiated
stimulator cells at a final volume of 200,l in wells ofround-bottomed microtiter plates
(Corning, Corning, NY). Plates were incubated at 370C, in humidified atmosphere
containing 5 percent CO2. After four days in culture [18], the wells were pulsed with I
,uCi of 3[H] thymidine for the final 18 hours of incubation. Cultures were harvested
with automated culture harvester (MASH, Cambridge). Incorporation of radioactiv-
ity was measured by liquid scintillation counting. Data were presented as delta cpm,
which represents the allogeneic stimulation response minus the response to autologous
irradiated cells. Mean values of six experiments in triplicates are presented with
standard error (SE). In the three-party inhibition experiments, increasing numbers of
responder cells (1, 2, 4, and 5 x 105) from either naive, sensitized, or PET-treated
BALB/c mice were suspended in media and co-cultured with stimulator cells. An
equivalent amount of cells from either PET-treated or sensitized mice was the third
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population of cells added to the wells. Cultures were incubated and harvested as
previously described. Data were presented as delta cpm, which represents the
allogeneic stimulation response minus the value obtained from the addition of the
response to autologous irradiated cells from both populations of responder cells. Mean
values of two to three experiments done in triplicate are given plus or minus SE.
Percentage ofinhibition was calculated by the formula: %Inhibition = [1 - (delta cpm
of sensitized or naive + PET-treated responder cells/delta cpm of sensitized+ naive
responder cells)] x 100.
Cytotoxicity Assay
Cytotoxicity assays were performed to detect the presence of alloreactive cells
primarily responsive to Class I alloantigen disparity [8]. Skin graft recipient, naive,
and PET-treated BALB/c mice were sacrificed, and a mononuclear cell suspension of
spleen cells was prepared. Splenocytes from graft recipient mice were restimulated in
vitro, following the methods of Buracoff et al. [19] and Granstein et al. [20]. Briefly,
8x 106 responder spleen cells were co-cultured with 3 x 106 erythrocyte-free
8-MOP-/UVA-inactivated skin donor strain (CBA/j) splenocytes in 24-well, flat-
bottomed microtiter plates (Falcon). Cultures were incubated for five days at 370C in a
humidified atmosphere containing 5 percent CO2. Cytotoxicity of effector cells was
assessed by testing concanavalin A-(Con A) stimulated splenocytes from skin donor
mice (CBA/j) orsyngeneic mice (BALB/c) as targets. Con A blasts were prepared by
two-day culture of 3 x107 spleen cells in the presence of 2.5,ug/ml of Con A (Sigma
Chemical Co., St. Louis, MO). Con A blasts were separated from non-viable cells by
Lympholyte M (Accurate Chemical, Westbury, NY) gradient flotation. Viable Con A
blasts were washed twice and used for5"chromium labeling. Labeling of the blast cells
was performed by incubating 3 x 107 recovered cells with 200 ,u of Na5"CrO4
(5 mCi/ml; Amersham Corp., Arlington Heights, IL) for 90 minutes, shaking the
suspension every 15 minutes.
The chromium release assay was performed in flat-bottomed microtiter plates
(Falcon, Becton Dickinson & Company, Oxnard, CA) by the addition of1 x I04
5"Cr-labeled target cells to 1, 2, 4, and 8 x105 effector cells in a total volume of 200,ul
of media. The plates were centrifuged (300 g, one minute) at the beginning of the
assay, incubated for four to five hours at 370C, and centrifuged again (500 g, 1 50C, ten
minutes). A volume of100,ul of media was removed from each well and dissolved in 3
cc of Biocount (Research Products International Corp., Mt. Prospect, IL) for liquid
scintillation counting. Percentage ofspecific5"Cr release was calculated according to
the formula E-S/M-S x 100, in which E is the isotope release in the presence of
effector cells, S is thespontaneous isotope release in the presence of medium, and M is
the maximal release obtained by adding to target cells an equal volume of1 percent
Triton X-100. The results are reported as the mean percentage of specific release of
three experiments performed in triplicate with spontaneous release of the isotope not
higher than 20 percent. Inhibition experiments were performed by culturing 4 x 106
splenocytes from either naive or sensitized mice mixed with 4 x 106 splenocytes from
PET-treated mice in the presence of 3 x 106 8-MOP/UVA-inactivated splenocytes
from skin donor mice (CBA/j). Chromium-labeled targets were prepared as described
above. Determination of the 5'Cr specific release was performed and reported as
previously described.
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TABLE 1
Autologous Mixed Leukocyte Response
CPM [3H] thymidine (X + SE)'
Number of Responder H-2 and Mls Haplotypec Naive BALB/c Sensitized PET tx
Cells x 105b Stimulator Cells Mice BALB/c BALB/c
(H2d, Mlsb) 2 x 10 n = 3 n = 3 n = 6
I HH2d Mlsb 250 + 73 281 + 32 4,907 + 620
2 H-2d Mlsb 806 + 39 1,630 + 293 32,045 + 3,811
4 H-2d Mlsb 5,577 + 1,044 7,767 + 715 46,820 + 2,339
8 H-2d Mlsb 14,980 + 787 15,087 + 627 45,147 + 5,044
aThese results are the background values for the experiments presented in Fig. 1.
'The responder cell population (naive, sensitized, or PET x BALB/c splenocytes) were aliquoted at
increasing concentrations ofcells/well in triplicate and tested for [3H] thymidine incorporation.
cX-irradiated splenocytes from naive BALB/c mice were aliquoted as stimulator cells at 2 x 105
cells/well.
Delayed-Type Hypersensitivity Response
DTH assay was performed following the methods of Granstein et al. [20] and Van
der Kwast et al. [21] and represent in vivo allogenic responses to histoincompatible
Class II alloantigens [7]. Spleen cell suspension from CBA/j mice (30-50 x 106
X-irradiated splenocytes) were injected in the flank of five naive BALB/c mice
(positive control group), five PET-treated BALB/c mice (experimental group 1), and
five BALB/c mice treated with photoinactivated naive splenocytes (experimental
group 2). For elicitation, the previously immunized groups ofmice as well as five naive
BALB/c mice (negative control group) received 10 x 106 CBA/j splenocytes injected
subcutaneously in the right hind footpad in 0.20 ml of PBS. After 24 hours, both hind
footpads were measured for thickness with a dial caliper (Monostat, Swiss-made
Fisher Scientific, Springfield, NJ). The thickness ofthe left footpad (noninjected) was
subtracted from the right (injected) footpad to measure the DTH response. Percentage
of suppression was calculated by the formula: 1 - (E-N/P-N) x 100, where E is the
measurement obtained from the experimental group ofmice, Nis the negative control,
and Pis the positive control. Specific suppression ofthe DTH response was determined
by immunizing and challenging analogous groups of mice with splenocytes from
C57BI/10 mice (H-2b).
Statistical Analysis
Statistical significance was determined according to student's t test. Apvalue ofless
than 0.05 was considered significant.
RESULTS
Specific Suppression ofMLC
BALB/c female mice, immunized with syngeneic PET cells, demonstrated a highly
significant (p < 0.001) autologous response (Table 1) at all numbers ofresponder cells
tested and also showed a highly significant hyporesponsiveness to H-2k, Mlsd alloan-
tigen in MLC, when compared to the proliferative response of splenocytes obtained
from either naive (Fig. la) or sensitized BALB/c mice. When splenocytes from
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FIG. 1. Proliferative response in mixed leukocyte culture of
splenocytes from BALB/c mice. The response of: a, PET-
treated BALB/c splenocytes (O~) to H-2k, Mlsd alloantigen
expressed on CBA/j spleen cells compared to the proliferative
response of naive (0) and sensitized (A) BALB/c spleen
cells. h, PET-treated BALB/c splenocytes (O) to an irrele-
vant alloantigen H-2b, Mlsb, expressed on BIO stimulator
splenocytes compared to sensitized BALB/c splenocytes
(A). c, Naive BALB/c mice (0) to H-2k, Mlsd alloantigen
compared to splenocytes from naive BALB/c mice added in a
1:1 ratio to either sensitized (-) BALB/c splenocytes or
PET-treated (*) BALB/c splenocytes. d, Sensitized BALB/
c splenocytes (A) to H-2k, Mlsd compared to sensitized BALB/
c splenocytes added 1:1 to either naive (-)or PET-treated (A)
BALB/c splenocytes. e, Sensitized BALB/c splenocytes (A)
to an irrelevant alloantigen H-2b, Mlsb compared to sensitized
BALB/c splenocytes added in a 1:1 ratio to either naive (@) or
PET-treated (-) BALB/c splenocytes.
PET-treated BALB/c mice were exposed in MLC to H-2b, Mlsb, however, an
irrelevant alloantigen, the proliferative response was comparable to that ofsplenocytes
from sensitized BALB/c mice (Fig. 1b). Therefore, specific hypoproliferative response
in MLC to the relevant MHC antigens could be induced by immunization with PET
cells. Thus, this specific hyporesponsiveness could be the result of deletion of the
effector cell population mediating the recognition ofthe target alloantigen or inhibition
of the effector cells mediated by a suppressive cell population in the spleens of
PET-treated mice. Therefore, a three-party MLC was performed to determine
whether the MLC hyporesponsiveness resulted from a deletion of the effector cell
population or whether an inhibitory cell population had been generated (Fig. ic, id).
As anticipated, when splenocytes from sensitized BALB/c mice were admixed equally
(1:1) with splenocytes from naive BALB/c mice and then stimulated with CBA/j, an
augmented proliferative response, over that ofnaive BALB/c cells alone, was obtained.
When splenocytes from mice pre-treated with PET cells were similarly admixed with
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cells from naive mice, however, the proliferative response was markedly suppressed
(>100 percent) (p < 0.001) (Fig. Ic). Similar results wereobtained afteradmixing the
splenocytes from PET-treated mice with the cells from sensitized mice (p < 0.001)
(Fig. Id). When splenocytes from sensitized and PET-treated mice were admixed and
exposed to X-irradiated cells bearing the irrelevant antigen H-2b, Mlsb, however, some
suppression was observed (lowest p value, <0.02) but not to the extent of the
suppression demonstrated to the H-2k, Mlsd alloantigen (p < 0.001) (Fig. Ie). There-
fore, the diminution of MLC reactivity against donor antigens in splenocytes from
PET-treated mice resulted from the presence ofa specific inhibitory cell population.
Suppression ofCytotoxicity
To evaluate the capacity to generate cytotoxic T cells from the spleens of
PET-treated BALB/c mice, 5'Cr-labeled CBA/j or BALB/c lymphoblasts were added
to an established BALB/c versus CBA/j MLC assay (Fig. 2). Although a maximal
specific cytotoxic T-cell response of 30 percent was obtained at 80:1 E:T ratio from
PET-treated BALB/c mice to 5'Cr-labeled CBA/j targets, this response was signifi-
cantly less than that observed in naive BALB/c splenocytes at 20, 40, and 80:1 E:T
ratio (p < 0.02, <0.005, and <0.005, respectively) to identical 5'Cr-labeled CBA/j
targets. Also, the specific cytotoxic T-cell response observed in spleen cells from
PET-treated BALB/c mice was significantly less than that ofsensitized BALB/c mice
at 10, 20, and 80:1 E:T ratio (p < 0.005, <0.001, and <0.001, respectively) (Fig. 2a).
There was less than 25 percent cytotoxic response elicited from the spleens of naive,
sensitized, or PET-treated mice to BALB/c 5'Cr-labeled target cells (Fig. 2b).
Therefore, specific hyporesponsive cytotoxic T-cell response to the original alloantigen
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presented by the skin graft can be observed in the spleen cells of PET-treated mice.
Thus, a three-party 5'Cr-release assay was performed to determine whether the
diminished cytotoxic response to CBA/j alloantigen from the spleens of PET-treated
BALB/c mice was the result of an inhibitory cell population or the deletion of the
effector T-cell population (Fig. 3). First, splenocytes from naive BALB/c mice were
admixed at a 1:1 ratio with cells from the PET-treated BALB/c mice and then
incubated with CBA/j stimulators. The subsequent addition of 5'Cr-labeled CBA/j
target lymphoblasts revealed a significant suppression at 40 and 80:1 E:T ratio
(p < 0.02 and <0.002, respectively) of the normally pronounced cytotoxic T-cell
response of naive BALB/c mice splenocytes to the CBA/j alloantigen (Fig. 3a).
Highly significant suppression ( p <0.005, <0.005, <0.001, and <0.001), at all E:T
ratios tested, ofthe sensitized BALB/c cytotoxic T-cell response to CBA/j alloantigen
was obtained when cells from the sensitized BALB/c mice were admixed with
splenocytes from the PET-treated BALB/c mice in the presence of inactivated CBA/j
splenocytes (Fig. 3b). The minimal autologous cytotoxic response of 25 percent
observed at 80:1 E:T ratio in splenocytes from naive BALB/c mice was also
significantly suppressed (p < 0.002) by the addition of cells from PET-treated mice
(Fig. 4a). The autologous cytotoxic T-cell response observed in splenocytes from
sensitized BALB/c mice was also suppressed (Fig. 4b) but not to a significant level.
Therefore, pre-exposure of the immune system to PET cells resulted in augmented
cell-mediated inhibition of the cytotoxic T-cell response to alloantigen.
Specific Inhibition ofDTH
DTH experiments were performed to demonstrate in vivo inhibition of the response
to alloantigen (Fig. 5). When PET-treated mice were primed on the flank and seven
days after the footpad challenged with H-2k, Mlsd alloantigen bearing lymphocytes, an
86 percent suppression of the DTH response (footpad swelling) was demonstrated asPEREZ ET AL.
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FIG. 4. Inhibition of autologous cyto-
toxic T-cell response. a. Naive BALB/c
mice splenocytes or b. sensitized BALB/
c mice splenocytes exposed to H-2k, Mlsd
alloantigen in vitro and tested for lysis of
BALB/c (H-2d, Mlsb) 5'Cr-labeled targets
at increasing effector-to-target ratios and
compared to lysis elicited when cells from
PET-treated mice were admixed 1:1 to (a)
100 naive BALB/c or (b) sensitized BALB/c
mice splenocytes.
compared with positive controls; however, no suppression of the DTH response was
demonstrated when PET-treated mice were primed and challenged with lymphocytes
bearing the unrelated antigen H2b.
When BALB/c mice treated with photoinactivated naive cells were primed in the
flank and seven days after the footpad challenge with H-2k, Mlsd alloantigen-bearing
lymphocytes, however, no suppression of DTH response (footpad swelling) was
demonstrated as compared with controls (Fig. 6).
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FIG. 5. Specific inhibition of delayed-type hypersensitivity response.
PET-treated BALB/c mice primed in the flank and footpad challenged with
either CBA/j (H-2k, MISd) (left) or B1O (H-2b, Mlsb) (right) splenocytes
and the measurements offootpad swelling compared to the swelling elicited
in positive and negative controls.
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FIG. 6. Delayed-type hypersensitivity of experimental control group 2.
BALB/c mice which had received intravenous infusions of 8-MOP/UVA
photoinactivated syngeneic naive splenocytes were primed in the flank and
footpad challenged with splenocytes from either CBA/j (H-2k, Mlsd) (left)
or BI0(H-2b, Mlsb) (right) mice and footpad swelling compared to swelling
elicited in control mice.
Allograft Retention
Finally, BALB/c mice which had been repeatedly infused with PET cells recogniz-
ing the H-2k, Mlsd (CBA/j) alloantigen were challenged with a fresh CBA/j skin
transplant, the survival of which was visually and histopathologically followed. Six
PET-treated BALB/c female mice received CBA/j skin transplants, in parallel with
naive BALB/c female mice which also received identical skin grafts. Treated mice
continued to receive intravenous PET infusions on a weekly basis, following engraft-
ment.
All control naive BALB/c mice demonstrated evidence of rejection by seven days
after transplant. In contrast, none of the PET-treated mice demonstrated any visual
evidence of rejection. Three PET-treated mice were sacrificed 18 days post-transplan-
tation. Their skin grafts did not show visual evidence ofrejection at that time, whereas
100 percent ofthe control mice transplants had already completely necrosed.
The surviving PET-treated mice were sacrificed at subsequent intervals for histolog-
ical evaluation of the graft. Although these mice did not demonstrate clear visual
evidence of rejection by the end of the third and seventh weeks, respectively, the
histopathology evaluation performed at the third week post-transplantation revealed
epidermotropism of mononuclear inflammatory cells within a viable epidermis.
Confluent and focal vacuolar epidermal basal cell degeneration and focal areas of
mononuclear cell infiltration ofengrafted epidermis with a denser dermal mononuclear
cell infiltrate were seen in the pathological specimens obtained from the fifth and
seventh week post-engraftment. Four BALB/c mice, however, which had received
similar amounts of photoinactivated splenocytes from syngeneic mice rejecting a
CBA/j skin graft, then received a skin graft from B1O mice, which was rejected within
seven days post-engraftment. The histologic evaluation of these skin grafts revealed
separation of a necrotic epidermis from the dermis, which contained a very dense
mononuclear cell infiltrate and thrombi formation within dermal vessels.
Therefore, pre-exposure ofthe mouse immune system to PET cells generated during
skin transplant rejection rendered the secondary syngeneic recipient relatively, but not
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necessarily absolutely, tolerant to the alloantigen carried by the transplanted donor
used to generate the immunizing effector cell population. In spite of these in vivo
lymphoid infiltrates suggesting a cellular response to the graft, substantial suppression
of MLC, CTL, and DTH was demonstrated, and prolongation of specific allograft
survival was observed.
DISCUSSION
urine skin transplantation across H-2 barriers results in transplant rejection
principally mediated by activated T lymphocytes ofthe recipient [5], which have been
identified as LytI +2+ [15] and L3T4+ positive [22].
In our study, CBA/j mice (H-2k, Mlsd) were selected as skin transplant donors
because of their disparity in the H-2 locus with BALB/c (H-2d, Misb) and their
stimulatory phenotype in the Mls locus, theoretically maximizing the expansion of
effector cells. The Mls locus is of interest because it is the only known genetic locus
other than the MHC in which strong proliferative response is observed between
unprimed individuals displaying disparity on it [23]. The simplest view of the Mls
system at present is that it is composed of a silent allele (Mlsb) and two independent
stimulatory alleles (Mls-a and c) [24] and the co-expression of both stimulatory
determinants (Mlsa+c=d) results in the Mlsd phenotype. By transplanting CBA/j skin
onto BALB/c mice, the allografted mice should develop Tc effector cells which
recognize Class I antigens and Tdth lymphocytes, possibly of theThl [25] helper cells
which recognized ClassII antigens, and possibly, L3T4+ cells responding to the
Mls-modified products of the MHC [26]. We appear to have inhibited this response
significantly with our PET immunization protocol.
Our data demonstrate that this novel immunization protocol leads to the develop-
ment ofsignificantly diminished responsiveness to alloantigen and that this inhibition
reflects the presence of cells capable of inhibiting the specific response to H-2k, Mlsd
alloantigen in MLC, CTL, and DTH reactions. Moreover, a substantial increase in the
length of skin graft survival was obtained. Our findings extend those reported in other
systems by various investigators [27-29]. Rohowsky and Suciu-Foca [27] have shown
that idiotype-like receptors for alloantigens on autologous T lymphoblasts stimulate
the autologous MLC (AMLC) response in resting lymphocytes. In our studies, a
substantial increase in the AMLC response has been observed in the splenocytes of
PET-treated animals (Table 1). Dorsch and Roser [28] demonstrated a rapidly
recirculating suppressor T-cell population in animals rendered tolerant to alloantigen
by transfusion ofallogeneic bone marrow cells during the neonatal period of life. These
cells are capable of adoptively transferring tolerance, in irradiated syngeneic recip-
ients, to skin transplants bearing the alloantigens to which the original tolerance was
induced, without interfering with the rejection of an unrelated skin graft. In our
system, we have demonstrated the presence of a cell population capable of specifically
ameliorating theresponse in MLC, CTL, and DTH to the antigen used to generate the
effector cell population, while sparing theresponse to an irrelevant antigen. Bellgrau et
al. [29] induced tolerance to parental lymphocytes, in F, rats, by immunizing them
with lymphocytes bearing the MHC receptors for specific parental strains of lympho-
cytes. In an analogous fashion, we induced hyporesponsiveness to alloantigen by
immunizing syngeneic mice with splenocytes containing cells bearing the MHC
receptor for a specific histoincompatible antigen carried by the skin graft.
In this report, we describe a method ofinducing tolerance that may be practical even
in a clinical setting. In ourstudies, the host selects the appropriate immunoreactive cell
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type from a mixed splenocyte pool which includes an expanded population of effector
BALB/c anti CBA/j lymphocytes. These anti H-2k, MISd lymphocytes would be the
cells most likely to induce a response in the secondary recipient naive BALB/c mice, on
a mere numerical basis. Moreover, Ben-Nun and Cohen [30] have demonstrated that
the induction of a suppressive clonotypic response is more efficiently attained if the
EAE-inducive T-cell clones used for vaccination have been activated in vitro with the
antigen and attenuated either with X-irradiation or mytomicin C prior to reinfusion.
If, however, viable EAE-inducing T-cell clones are intravenously infused, acute onset
paralysis characteristic of EAE develops in the recipient animals. In our protocol, we
have used in vivo activation by skin grafting to expand effector cells and use these cells
obtained at the peak ofrejection for immunization. The anti-H-2k, Mlsd T-cell-specific
contribution to these results may be better ascertained after we have cloned, photoinac-
tivated, and infused them (either alone or in varying ratios with bystander spleno-
cytes). Under these conditions, it will also be of interest to determine whether
nonspecific bystander splenocytes exert either an adjuvant or interference effect. These
studies are in progress.
The identity ofthese cells remains to be established. It will be necessary to determine
whether they are Ly2+ suppressor T cells [31] or Ly2+ anti-receptor anti-MHC
cytotoxic T cells described by Kosmatopoulos et al. [32] or the CD8+ cells which
specifically respond to determinants on the disease-mediating T-cell clones [33].
In our system, photoinactivation with 8-MOP might have been so effective in
maximizing the development of a specific inhibitory response to alloantigen because it
reflects the ability to control two variables (drug dose and UVA energy), which limit
the chemical reaction to microseconds [34], and thus makes possible meticulous
control of the dose-response curve of cellular inactivation to a level not previously
attainable. Significantly, 8-MOP-UVA pre-treatment of cloned anti-basic myelin
protein T cells [35] was more effective than X-irradiation of the same cells for
vaccinating rats against the induction of EAE. Second, our studies on the suppression
of DTH response to sheep red blood cells [36] have demonstrated that 8-MOP-UVA
treatment of naive population of splenocytes is ineffective in inducing suppression,
indicating that the presence of expanded population(s) of specific effector T cells are
necessary. Third, Laskin et al. [37] have identified specific, saturable, high-affinity
binding sites for 8-MOP on mice and human cell lines which might be a cell surface
binding site that becomes covalently modified by exposure to UVA-modifying cellular
antigenicity. It must be emphasized, however, that 8-MOP-UVA pre-treatment of
effector cells may be merely one means ofinducing the observed results.
In summary, we conclude that it is possible to induce a state of hyporeactivity
against a specific set of MHC antigens. Syngeneic effector cells with specificity for
these antigens can be photoinactivated and used as immunogens to induce this
hyporesponsive state. Since a method for photoinactivating effector T cells in
analogous fashion with that used here has been successful in the treatment of CTCL
patients [4] and is currently being tested in other T-cell-mediated disorders, our
protocol may have potential application in the field oftransplantation in humans.
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